Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cencora, Inc. Common Stock (NY:COR)

279.00 +0.62 (+0.22%)
Official Closing Price Updated: 7:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cencora, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,300 Today
Via Benzinga
How Is The Market Feeling About Cencora?
Via Benzinga
3 Biotech Stocks You’ll Regret Not Buying Soon: November 2023
The global biotechnology market could nearly triple by 2030. Investors should consider buying these biotech stocks before they explode. 
Via InvestorPlace
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
From Cencora
Via Business Wire
Here's How Much $1000 Invested In Cencora 5 Years Ago Would Be Worth Today
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $12,000 Today
Via Benzinga
Peering Into Cencora's Recent Short Interest
Via Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
Obesity And Diabetes Drugs Demand Help Distributor Cencora Propel Revenue In Q3
Cencora Inc's (NYSE: COR), formerly AmerisourceBergen Corporation,  
Via Benzinga
Cencora Reports Fiscal 2023 Fourth Quarter and Year End Results
From Cencora
Via Business Wire
Peering Into Cencora's Recent Short Interest
Via Benzinga
$100 Invested In Cencora 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years
Via Benzinga
Earnings Due For Stealth GLP-1 Weight-Loss Drug Play McKesson, Rivals
McKesson earnings are on tap, with Cencora and Cardinal Health due soon. 
Via Investor's Business Daily
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities. 
Via MarketBeat
Cencora, Formerly AmerisourceBergen, Announces Date and Time for Fourth Quarter Fiscal 2023 Earnings Release
From Cencora
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 57 companies reached new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.